• 15 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
    Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy  [...] Read more.
    Pierluigi De Santis ... Palma Fedele
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:232–250
    DOI: https://doi.org/10.37349/etat.2024.00215
    This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
    View:877
    Download:31
    Times Cited: 0
    Open Access
    Case Report
    A case of immunotherapy-induced thyroiditis
    Immunotherapy treatments for cancer are known to cause adverse thyroid events which present a diagnostic challenge to clinicians and radiologists. This case report highlights the importance of a hig [...] Read more.
    George Pears ... Joseph Sacco
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:225–231
    DOI: https://doi.org/10.37349/etat.2024.00214
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:556
    Download:21
    Times Cited: 0
    Open Access
    Review
    Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
    Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventio [...] Read more.
    Hiroki Goto ... Seiji Okada
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:208–224
    DOI: https://doi.org/10.37349/etat.2024.00213
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:633
    Download:27
    Times Cited: 0
    Open Access
    Review
    Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment
    Cancer is the leading cause of death globally superseded only by cardiovascular diseases, and novel strategies to overcome therapeutic resistance against existing cancer treatments are urgently requ [...] Read more.
    Eric Jou ... Fizza Nasim
    Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:187–207
    DOI: https://doi.org/10.37349/etat.2024.00212
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    Open Access
    Review
    Conceptual breakthroughs of the long noncoding RNA functional system and its endogenous regulatory role in the cancerous regime
    Long noncoding RNAs (lncRNAs) derived from noncoding regions in the human genome were once regarded as junks with no biological significance, but recent studies have shown that these molecules are h [...] Read more.
    Anyou Wang
    Published: February 27, 2024 Explor Target Antitumor Ther. 2024;5:170–186
    DOI: https://doi.org/10.37349/etat.2024.00211
    View:518
    Download:13
    Times Cited: 0
    Open Access
    Review
    Exploring monocarboxylate transporter inhibition for cancer treatment
    Cells are separated from the environment by a lipid bilayer membrane that is relatively impermeable to solutes. The transport of ions and small molecules across this membrane is an essential process [...] Read more.
    Tomas Koltai, Larry Fliegel
    Published: February 23, 2024 Explor Target Antitumor Ther. 2024;5:135–169
    DOI: https://doi.org/10.37349/etat.2024.00210
    This article belongs to the special issue Therapeutic Targeting of Tumor Metabolism
    View:504
    Download:23
    Times Cited: 0
    Open Access
    Review
    The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates
    Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancers with high mortality rate. Among its various etiological factors, one of the major risk factors for HCC is a chronic [...] Read more.
    Agustiningsih Agustiningsih ... Caecilia Sukowati
    Published: February 20, 2024 Explor Target Antitumor Ther. 2024;5:120–134
    DOI: https://doi.org/10.37349/etat.2024.00209
    This article belongs to the special issue Molecular Targeted Therapy for Cancer
    View:618
    Download:22
    Times Cited: 0
    Open Access
    Mini Review
    Exploring the function of myeloid cells in promoting metastasis in head and neck cancer
    Head and neck cancer (HNC) is a challenging disease that lacks effective treatment, particularly in the cases that spread locoregionally and metastasize distantly, dramatically reducing patient surv [...] Read more.
    Dakota Dike Dimegwu Okwuone ... Gregory N. Gan
    Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:108–119
    DOI: https://doi.org/10.37349/etat.2024.00208
    This article belongs to the special issue Therapeutic Targeting of the Tumor Microenvironment
    View:1235
    Download:22
    Times Cited: 0
    Open Access
    Review
    CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia
    Monoclonal antibodies (mAbs) are an effective drug for targeted immunotherapy in several cancer types. However, so far, no antibody has been successfully developed for certain types of cancer, inclu [...] Read more.
    Kamonporn Kotemul ... Nuchjira Takheaw
    Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:96–107
    DOI: https://doi.org/10.37349/etat.2024.00207
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    View:588
    Download:16
    Times Cited: 0
    Open Access
    Mini Review
    Management of stage III non-small-cell lung cancer: rays of hope
    Lung cancer remains the most common cause of cancer death across the world. Non-small-cell lung cancer (NSCLC) represents the most frequent type of lung cancer and is frequently diagnosed at an adva [...] Read more.
    Floryane Kim ... Alex Friedlaender
    Published: February 19, 2024 Explor Target Antitumor Ther. 2024;5:85–95
    DOI: https://doi.org/10.37349/etat.2024.00206
    This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer
    View:597
    Download:31
    Times Cited: 0